XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Analysis of entities with the lowest risk in crypto, plus how to interpret liquidity, use case maturity, and developer activity for safer bets.
28,397 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Vertex is pursuing Crinetics with a substantial all-cash offer. This deep dive breaks down what the $10 billion bid m...
A big fund trimmed its ACMR stake, yet the stock jumped 170% in a short window. This article breaks down what happene...
This summer’s hottest IPOS are creating a surge of new wealth among employees and pressuring family offices to adapt ...
Oil prices surged to a peak near $119 before pulling back, creating a volatile week for markets. Here are three takea...
A major move in consumer finance tests whether a bank can grow its wallet while keeping customers happy. This article...
Got $10,000 and a goal to generate reliable cash from dividends? This guide shows how to pick the smartest dividend s...
Thinking about turning a solid investment into a multi-bagger? This guide outlines five stock ideas with the potentia...
XOVR, the $1.5 billion ETF that blends pre-IPO SpaceX exposure with public-growth stocks, is drawing renewed scrutiny...
Casual dining is turning a corner. Chili's posted an eye-catching 8.6% same-store sales gain, signaling a broader shi...
As AI-driven demand accelerates, the real trade sits with the equipment suppliers that power chip production. ASML, A...
A Bloomberg-sparked rumor could change how AI compute is bought and sold. If Amazon starts selling its custom AI chip...